Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old

Inclusion Criteria:

1. Children of both sexes at the age of 1 to 6 years old inclusive;

2. Diagnosis "Viral and other specified intestinal infections" (code according to theInternational Statistical Classification of Diseases and Related Health Problems 10th Revision(ICD-10): A08),

3. Clinical signs of endogenous intoxication (nausea, vomiting, hyperthermia, headache,muscle pain, asthenia, adynamia, etc.);

4. Indication for parenteral rehydratation (infusion therapy);

5. Decision of a physician on prescribing drug product Reamberin® solution forinfusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") in thedaily dose of 10 mL/kg and normal saline NaCl/5 % or 10 % solution of glucose ornormal saline NaCl/Ringer's solution/5 % or 10 % solution of glucose;

6. To confirm the diagnosis by laboratory tests, biological material was taken;

7. Informed Consent Form on Participation in the Observational Program signed and datedby a parent/legal representative of the patient.

Exclusion Criteria:

1. Individual intolerance or known hypersensitivity to sodium meglumine, sodiumsuccinate, and/or normal saline (NaCl), solution of glucose, Ringer's solution orexcipients of drug product Reamberin® based on data of medical history;

2. Contraindications to prescription of drug product Reamberin®;

3. Necessity in surgical interventions during the observational program;

4. Patients previously enrolled in this trial but discontinued participation due to anyany reason;

5. Administration of antibiotics or succinate-containing drug products (Cytoflavin,Mexidol, etc.) and solutions containing malate;

6. Other conditions that, according to the Investigator, prevent enrollment of apatient into the observational trial or can result in premature discontinuation ofthe observational trial by the patient